
News|Articles|March 1, 2002
Arixtra (Fondaparinux sodium injection), Organon/Sanofi-Synthelabo
New biologic: Factor Xa inhibitor for reducing risk of blood clotsafter orthopedic surgeries
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
Higher serotonin levels are associated with schizophrenia in general and negative symptoms specifically, a neuroimaging study finds
5

















































